

# A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma

Pratt, Guy; Yap, Christina; Oldreive, Ceri; Slade, Daniel; Bishop, Rebecca; Griffiths, Mike; Dyer, Martin J S; Fegan, Chris; Oscier, David; Pettitt, Andrew; Matutes, Estella; Devereux, Stephen; Allsup, David; Bloor, Adrian; Hillmen, Peter; Follows, George; Rule, Simon; Moss, Paul; Stankovic, Tatjana

DOI:  
[10.1111/bjh.14793](https://doi.org/10.1111/bjh.14793)

License:  
Other (please specify with Rights Statement)

Document Version  
Peer reviewed version

Citation for published version (Harvard):  
Pratt, G, Yap, C, Oldreive, C, Slade, D, Bishop, R, Griffiths, M, Dyer, MJS, Fegan, C, Oscier, D, Pettitt, A, Matutes, E, Devereux, S, Allsup, D, Bloor, A, Hillmen, P, Follows, G, Rule, S, Moss, P & Stankovic, T 2018, 'A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma', *British Journal of Haematology*, vol. 182, no. 3, pp. 429-433. <https://doi.org/10.1111/bjh.14793>

[Link to publication on Research at Birmingham portal](#)

## Publisher Rights Statement:

This is the peer reviewed version of the following article: Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., Dyer, M. J. S., Fegan, C., Oscier, D., Pettitt, A., Matutes, E., Devereux, S., Allsup, D., Bloor, A., Hillmen, P., Follows, G., Rule, S., Moss, P. and Stankovic, T. (2017), A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. *Br J Haematol*. doi:10.1111/bjh.14793, which has been published in final form at 10.1111/bjh.14793. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Download date: 24. Apr. 2024

Table 1: Trial Patient Summary

Treatment	TNO	Gender	Time from Diag (Years)	Age (years)	Disease Type	Prev of Treatment (N)	Time on Treatment (days)	Discontinuation Reason	Rea- DLT	Mutation: ATM or SF3B1
Cohort 1 (200mg bd Capsule)	1	Male	4.57	74	CLL	1	112	Progression	No	Mutated
	2	Male	4.22	53	MCL	7	13	Toxicity	Yes	Unmutated
Cohort 2 (200mg bd Capsule)	3	Male	7.28	59	CLL	3	126	Progression	No	Mutated
	4	Male	11.39	71	CLL	5	64	Progression	No	Mutated
	5	Male	5.39	69	CLL	2	83	Progression	No	Mutated
Cohort 3 (400mg bd Capsule)	6	Male	9.43	75	CLL	4	71	Progression	No	Mutated
	7	Male	6.09	63	CLL	3	17	Withdraw Consent	Yes	Unmutated
Cohort 4 (100mg bd Tablet)	8	Male	6.64	56	CLL	7	40	Death	Yes	Unmutated
	9	Female	2.15	65	T-PLL	3	14	Withdraw Consent	Yes	Mutated
Cohort 5 (100mg bd Tablet)	10	Male	9.35	61	CLL	4	8	Toxicity	Yes	Mutated
	11	Male	5.63	74	MCL	3	76	Progression	No	Unmutated
	12	Male	2.3	77	MCL	1	103	No response - not strictly progression. BTKi available.	No	Unmutated
Cohort 5 (100mg bd Tablet)	13	Male	0.82	66	T-PLL	1	133	Progression	No	Mutated
	14	Male	10.25	72	MCL	6	35	Progression	No	Unmutated
	15	Female	13	77	CLL	6	83	Progression	No	Mutated